Alpha Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major alpha thalassemia markets are expected to exhibit a CAGR of 8.06% during 2024-2034.
The alpha thalassemia market has been comprehensively analyzed in IMARC's new report titled "Alpha Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" Alpha thalassemia refers to a hereditary blood disorder characterized by reduced or absent production of alpha globin chains, essential components of hemoglobin, the protein responsible for delivering oxygen in red blood cells. The indications of the ailment can vary widely, ranging from mild to severe. In its gentler forms, individuals suffering from this illness may experience no symptoms or only mild anemia, which might go unnoticed. However, more severe cases can lead to fatigue, pale skin, weakness, and enlargement of the spleen. Newborns affected by alpha thalassemia major often exhibit hydrops fetalis, a life-threatening condition marked by severe edema and organ failure. The diagnosis of this ailment involves a comprehensive evaluation of various methods, including blood tests to measure hemoglobin levels and determine the ratio of alpha to beta globin chains. DNA analysis using several techniques is also utilized to confirm the presence of genetic mutations responsible for the condition.
The escalating prevalence of genetic disorders causing mutations in the HBA1 and HBA2 genes, which are crucial for the formation of alpha-globin chains, is primarily driving the alpha thalassemia market. In addition to this, the inflating utilization of effective therapeutic interventions, including blood transfusions and iron chelation therapy, to manage disease symptoms, mitigate complications, and enhance the quality of life for patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, such as folic acid supplementation and regular monitoring of iron levels, that help to improve therapy outcomes in individuals suffering from alpha thalassemia is further bolstering the market growth. Apart from this, the rising usage of advanced genetic testing and prenatal screening techniques in early diagnosis and risk assessment of the illness is acting as another significant growth-inducing factor. These diagnostic approaches enable timely medical interventions and informed decision-making for expectant parents. Additionally, the emerging popularity of hematopoietic stem cell transplantation procedures, since they boost the production of healthy red blood cells within the body to eliminate the need for lifelong transfusions and reduce complications related to iron overload, is expected to drive the alpha thalassemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the alpha thalassemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alpha thalassemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alpha thalassemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alpha thalassemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the alpha thalassemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current alpha thalassemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the alpha thalassemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the alpha thalassemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the alpha thalassemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of alpha thalassemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha thalassemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha thalassemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with alpha thalassemia across the seven major markets?
What is the size of the alpha thalassemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of alpha thalassemia?
What will be the growth rate of patients across the seven major markets?
Alpha Thalassemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for alpha thalassemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alpha thalassemia market?
What are the key regulatory events related to the alpha thalassemia market?
What is the structure of clinical trial landscape by status related to the alpha thalassemia market?
What is the structure of clinical trial landscape by phase related to the alpha thalassemia market?
What is the structure of clinical trial landscape by route of administration related to the alpha thalassemia market?
The alpha thalassemia market has been comprehensively analyzed in IMARC's new report titled "Alpha Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" Alpha thalassemia refers to a hereditary blood disorder characterized by reduced or absent production of alpha globin chains, essential components of hemoglobin, the protein responsible for delivering oxygen in red blood cells. The indications of the ailment can vary widely, ranging from mild to severe. In its gentler forms, individuals suffering from this illness may experience no symptoms or only mild anemia, which might go unnoticed. However, more severe cases can lead to fatigue, pale skin, weakness, and enlargement of the spleen. Newborns affected by alpha thalassemia major often exhibit hydrops fetalis, a life-threatening condition marked by severe edema and organ failure. The diagnosis of this ailment involves a comprehensive evaluation of various methods, including blood tests to measure hemoglobin levels and determine the ratio of alpha to beta globin chains. DNA analysis using several techniques is also utilized to confirm the presence of genetic mutations responsible for the condition.
The escalating prevalence of genetic disorders causing mutations in the HBA1 and HBA2 genes, which are crucial for the formation of alpha-globin chains, is primarily driving the alpha thalassemia market. In addition to this, the inflating utilization of effective therapeutic interventions, including blood transfusions and iron chelation therapy, to manage disease symptoms, mitigate complications, and enhance the quality of life for patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, such as folic acid supplementation and regular monitoring of iron levels, that help to improve therapy outcomes in individuals suffering from alpha thalassemia is further bolstering the market growth. Apart from this, the rising usage of advanced genetic testing and prenatal screening techniques in early diagnosis and risk assessment of the illness is acting as another significant growth-inducing factor. These diagnostic approaches enable timely medical interventions and informed decision-making for expectant parents. Additionally, the emerging popularity of hematopoietic stem cell transplantation procedures, since they boost the production of healthy red blood cells within the body to eliminate the need for lifelong transfusions and reduce complications related to iron overload, is expected to drive the alpha thalassemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the alpha thalassemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alpha thalassemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alpha thalassemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alpha thalassemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the alpha thalassemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current alpha thalassemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the alpha thalassemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the alpha thalassemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the alpha thalassemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of alpha thalassemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha thalassemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha thalassemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with alpha thalassemia across the seven major markets?
What is the size of the alpha thalassemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of alpha thalassemia?
What will be the growth rate of patients across the seven major markets?
Alpha Thalassemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for alpha thalassemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alpha thalassemia market?
What are the key regulatory events related to the alpha thalassemia market?
What is the structure of clinical trial landscape by status related to the alpha thalassemia market?
What is the structure of clinical trial landscape by phase related to the alpha thalassemia market?
What is the structure of clinical trial landscape by route of administration related to the alpha thalassemia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALPHA THALASSEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALPHA THALASSEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALPHA THALASSEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ALPHA THALASSEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALPHA THALASSEMIA - UNMET NEEDS
10 ALPHA THALASSEMIA - KEY ENDPOINTS OF TREATMENT
11 ALPHA THALASSEMIA - MARKETED PRODUCTS
11.1 List of Alpha Thalassemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ALPHA THALASSEMIA - PIPELINE DRUGS
12.1 List of Alpha Thalassemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Mitapivat - Agios Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ALPHA THALASSEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALPHA THALASSEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALPHA THALASSEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Alpha Thalassemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Alpha Thalassemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Alpha Thalassemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Alpha Thalassemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Alpha Thalassemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Alpha Thalassemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Alpha Thalassemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Alpha Thalassemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Alpha Thalassemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Alpha Thalassemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Alpha Thalassemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Alpha Thalassemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Alpha Thalassemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Alpha Thalassemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Alpha Thalassemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Alpha Thalassemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Alpha Thalassemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Alpha Thalassemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Alpha Thalassemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Alpha Thalassemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Alpha Thalassemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Alpha Thalassemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Alpha Thalassemia - Access and Reimbursement Overview
16 ALPHA THALASSEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALPHA THALASSEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALPHA THALASSEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALPHA THALASSEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALPHA THALASSEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALPHA THALASSEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ALPHA THALASSEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALPHA THALASSEMIA - UNMET NEEDS
10 ALPHA THALASSEMIA - KEY ENDPOINTS OF TREATMENT
11 ALPHA THALASSEMIA - MARKETED PRODUCTS
11.1 List of Alpha Thalassemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ALPHA THALASSEMIA - PIPELINE DRUGS
12.1 List of Alpha Thalassemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Mitapivat - Agios Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ALPHA THALASSEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALPHA THALASSEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALPHA THALASSEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Alpha Thalassemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Alpha Thalassemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Alpha Thalassemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Alpha Thalassemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Alpha Thalassemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Alpha Thalassemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Alpha Thalassemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Alpha Thalassemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Alpha Thalassemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Alpha Thalassemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Alpha Thalassemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Alpha Thalassemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Alpha Thalassemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Alpha Thalassemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Alpha Thalassemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Alpha Thalassemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Alpha Thalassemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Alpha Thalassemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Alpha Thalassemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Alpha Thalassemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Alpha Thalassemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Alpha Thalassemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Alpha Thalassemia - Access and Reimbursement Overview
16 ALPHA THALASSEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALPHA THALASSEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALPHA THALASSEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
